Astra goes early in small cell
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
Merck makes haste to catch up in KRAS
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Immutep approaches Lag3 crunch time
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
Merck matches Kelun’s saci-tirumo efforts
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
